Which biotech company does Vertex admire? Hint: It’s one some analysts think the cystic fibrosis drugmaker should have snapped up a long time ago. The “analogy that we’ve often talked about is with ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, Vertex's revenue soared 11% to more than $3 billion -- that's with net ...

Biotech stocks can generate eye-catching returns on capital in a few short years. For example, Vertex Pharmaceuticals (NASDAQ: VRTX) and Galapagos N.V. (NASDAQ: GLPG) have both made early investors ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden its ...

According to data fromS&P Global Market Intelligence, shares of the rare disease specialistVertex Pharmaceuticals (NASDAQ: VRTX) rose by 16.6% last month. The drugmaker's shares appear to have ...

Biotech stocks can generate eye-catching returns on capital in a few short years. For example, Vertex Pharmaceuticals (VRTX +0.60%) and Galapagos N.V. (GLPG 0.64%) have both made early investors ...

The big-ticket item that seems to have lit on fire underneath Vertex's stock last month is the immense growth within the company's core cystic fibrosis franchise over the past year. Per its Q4 ...